Literature DB >> 29128050

The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.

Nadege T Gunn1, Mitchell L Shiffman2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder that can be divided into benign steatosis or nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). Elastography and scoring systems based on clinical features and routine biochemical testing can be used to assess fibrosis in patients with NAFLD. Patients with fibrosis are thought to have NASH. However, only a liver biopsy can reliably diagnose NAFLD and differentiate NAFL from NASH. Because medical therapy for NASH is not available, it is not necessary to perform a liver biopsy in all patients. Patients suspected of having NASH should undergo liver biopsy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Elastography; Liver biopsy; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2018        PMID: 29128050     DOI: 10.1016/j.cld.2017.08.006

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  13 in total

Review 1.  Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.

Authors:  Jia-Zhen Zhang; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-22

2.  Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD.

Authors:  Giulio Argalia; Claudio Ventura; Niccolò Tosi; Daniele Campioni; Corrado Tagliati; Marianna Tufillaro; Monica Cucco; Gianluca Svegliati Baroni; Andrea Giovagnoni
Journal:  Radiol Med       Date:  2022-03-15       Impact factor: 6.313

Review 3.  Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones.

Authors:  K Pafili; S A Paschou; E Armeni; S A Polyzos; D G Goulis; I Lambrinoudaki
Journal:  J Endocrinol Invest       Date:  2022-03-18       Impact factor: 5.467

Review 4.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

Review 5.  Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.

Authors:  Byung Wan Lee; Yong Ho Lee; Cheol Young Park; Eun Jung Rhee; Won Young Lee; Nan Hee Kim; Kyung Mook Choi; Keun Gyu Park; Yeon Kyung Choi; Bong Soo Cha; Dae Ho Lee
Journal:  Diabetes Metab J       Date:  2020-05-11       Impact factor: 5.376

Review 6.  Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.

Authors:  Dae Ho Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

7.  Chinese Herbal Medicine Formula Shenling Baizhu San Ameliorates High-Fat Diet-Induced NAFLD in Rats by Modulating Hepatic MicroRNA Expression Profiles.

Authors:  Maoxing Pan; Yuanjun Deng; Chuiyang Zheng; Huan Nie; Kairui Tang; Yupei Zhang; Qinhe Yang
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-14       Impact factor: 2.629

8.  (13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle.

Authors:  Emilio Molina-Molina; Harshitha Shanmugam; Agostino Di Ciaula; Ignazio Grattagliano; Domenica Maria Di Palo; Vincenzo O Palmieri; Piero Portincasa
Journal:  JHEP Rep       Date:  2020-11-04

9.  The relationship between non-alcoholic fatty liver disease and hypothyroidism: A systematic review and meta-analysis.

Authors:  Xiaoxu Zeng; Bin Li; Yang Zou
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

10.  Circulating Neutrophils of Nonalcoholic Steatohepatitis Patients Show an Activated Phenotype and Suppress T Lymphocytes Activity.

Authors:  Laura Antonucci; Cristiana Porcu; Eleonora Timperi; Silvano Junior Santini; Gino Iannucci; Clara Balsano
Journal:  J Immunol Res       Date:  2020-06-30       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.